LENSAR, Inc.
Business
LENSAR, Inc. designs, develops and markets advanced robotic laser systems for cataract treatment and management of corneal astigmatism. Its products include the LENSAR Laser System (LLS) and the ALLY Robotic Cataract Laser System, featuring proprietary robotic imaging, AI-driven cataract density analysis, iris registration and a dual‑modality laser for precision and reproducibility. Operations encompass product development, manufacturing, regulatory affairs and commercial support for laser systems and accompanying software. Distribution channels include a U.S. direct sales organization and international third‑party distributors selling to surgeons, hospitals, ambulatory surgery centers and physician practices.
Summary from filing dated 2025-02-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product and service revenue | 52 | 46 | 36 | 29 | 29 | |
| Lease | 7 | 8 | 6 | 6 | 5 | |
| Total revenue | 58 | 53 | 42 | 35 | 34 | |
| Total cost of revenue | 31 | 28 | 21 | 15 | 17 | |
| Selling, general and administrative expenses | 45 | 26 | 26 | 27 | 24 | |
| Research and development expenses | 6 | 5 | 6 | 12 | 12 | |
| Amortization of intangible assets | 921,000 | 970,000 | 1 | 1 | 1 | |
| Impairment of intangible assets | 0 | 4 | 0 | — | — | |
| Total operating expenses | 52 | 37 | 33 | — | — | |
| Operating loss | −25 | −11 | −12 | −20 | −20 | |
| Change in fair value of warrant liabilities | −10 | −21 | −3 | — | — | |
| Other income, net | 636,000 | 660,000 | 698,000 | 263,000 | 51,000 | |
| Net loss | −34 | −31 | −14 | −20 | −20 | |
| Change in unrealized gain on investments | −2,000 | 2,000 | 4,000 | — | — | |
| Net loss and comprehensive loss | −34 | −31 | −14 | −20 | — | |
| Basic (per share) | −2.87 | −2.73 | −1.31 | −1.96 | −2.09 | |
| Diluted (per share) | −2.87 | −2.73 | −1.31 | −1.96 | −2.09 | |
| Basic (shares) | 12 | 12 | 11 | 10 | 9 | |
| Diluted (shares) | 12 | 12 | 11 | 10 | 9 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 16 | 21 | 15 | 32 | |
| Short-term investments | 5 | 6 | 3 | — | — | |
| Accounts receivable, net of allowance of $62 and $105, respectively | 6 | 6 | 4 | 6 | 5 | |
| Notes receivable, net of allowance of $6 and $8, respectively | 295,000 | 395,000 | 323,000 | 200,000 | 350,000 | |
| Inventories | 22 | 11 | 16 | 12 | 6 | |
| Prepaid and other current assets | 601,000 | 2 | 2 | 1 | 2 | |
| Total current assets | 47 | 42 | 46 | 34 | 45 | |
| Property and equipment, net | 505,000 | 664,000 | 679,000 | 563,000 | 756,000 | |
| Equipment under lease, net | 15 | 14 | 7 | 6 | 7 | |
| Notes and other receivables, long-term, net of allowance of $15 and $23, respectively | 731,000 | 1 | 1 | 442,000 | 121,000 | |
| Intangible assets, net | 5 | 6 | 11 | 12 | 11 | |
| Other assets | 3 | 3 | 2 | 3 | 3 | |
| Total assets | 71 | 66 | 70 | 56 | 66 | |
| Accounts payable | 19 | 6 | 4 | 5 | 3 | |
| Accrued liabilities | 8 | 7 | 6 | 5 | 5 | |
| Deferred revenue | 3 | 2 | 1 | 768,000 | 904,000 | |
| Operating lease liabilities | 747,000 | 524,000 | 559,000 | 531,000 | 512,000 | |
| Acquisition-related deposit | 10 | — | — | — | — | |
| Total current liabilities | 41 | 15 | 12 | 11 | 9 | |
| Long-term operating lease liabilities | 2 | 2 | 2 | 2 | 3 | |
| Warrant liabilities | 40 | 30 | 8 | — | — | |
| Other long-term liabilities | 909,000 | 702,000 | 570,000 | 167,000 | 69,000 | |
| Total liabilities | 84 | 48 | 22 | 14 | 12 | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 shares authorized at December 31, 2025 and 2024; 20 shares issued and outstanding at December 31, 2025 and 2024; aggregate liquidation preference of $20,000 at December 31, 2025 and 2024 | 14 | 14 | 14 | — | — | |
| Preferred stock, par value $0.01 per share, 9,980 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, par value $0.01 per share, 150,000 shares authorized at December 31, 2025 and 2024; 11,993 and 11,654 shares issued and outstanding at December 31, 2025 and 2024, respectively | 120,000 | 116,000 | 113,000 | 111,000 | 110,000 | |
| Additional paid-in capital | 151 | 148 | 145 | 139 | 132 | |
| Accumulated other comprehensive income | 4,000 | 6,000 | 4,000 | — | — | |
| Accumulated deficit | −178 | −143 | −112 | −98 | −78 | |
| Total stockholders' (deficit) equity | −26 | 5 | 33 | 42 | 55 | |
| Total liabilities, redeemable convertible preferred stock, and stockholders' (deficit) equity | 71 | 66 | 70 | 56 | 66 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −34 | −31 | −14 | −20 | −20 | |
| Depreciation | 4 | 3 | 2 | 2 | 2 | |
| Non-cash operating lease cost | 541,000 | 539,000 | 534,000 | 521,000 | 517,000 | |
| Provision for expected credit losses | −53,000 | 65,000 | 1,000 | 36,000 | 74,000 | |
| Write-down of inventory | 0 | 94,000 | 66,000 | 50,000 | 320,000 | |
| Loss on disposal of property and equipment | 58,000 | — | 7,000 | 11,000 | 133,000 | |
| Stock-based compensation expense | 3 | 3 | 6 | 7 | 7 | |
| Amortization on investments, net | −181,000 | −250,000 | −12,000 | — | — | |
| Accounts receivable | −211,000 | −2 | 2 | −1 | −3 | |
| Notes receivable | 500,000 | 87,000 | −980,000 | −180,000 | — | |
| Prepaid and other current assets | 1 | 751,000 | −1 | 637,000 | 157,000 | |
| Inventories | −14 | −5 | −7 | −7 | 2 | |
| Accounts payable | 13 | 2 | −1 | 3 | 213,000 | |
| Accrued liabilities | −341,000 | 1 | 892,000 | 96,000 | 75,000 | |
| Deferred revenue | 2 | 675,000 | 915,000 | −174,000 | — | |
| Operating lease liabilities | −511,000 | −559,000 | −539,000 | −512,000 | — | |
| Other | −49,000 | −84,000 | 60,000 | 156,000 | −166,000 | |
| Net cash used in operating activities | −15 | −2 | −10 | −15 | −9 | |
| Purchase of property and equipment | −83,000 | −156,000 | −236,000 | −115,000 | −354,000 | |
| Purchase of investments | −12 | −10 | −4 | — | — | |
| Maturities of investments | 13 | 8 | — | — | — | |
| Net cash provided by (used in) investing activities | 1 | −2 | −4 | −115,000 | −354,000 | |
| Proceeds from acquisition-related deposit | 10 | — | — | — | — | |
| Proceeds from issuance of common stock under employee stock purchase plan | 590,000 | 306,000 | 327,000 | 408,000 | 361,000 | |
| Proceeds from issuance of common stock through option exercises | 93,000 | 58,000 | — | — | — | |
| Net settlement of stock-based compensation awards | −425,000 | −188,000 | −52,000 | — | — | |
| Payment of accrued offering costs allocable to preferred stock | — | −98,000 | — | — | — | |
| Net cash provided by financing activities | 10 | 78,000 | 20 | −2 | 361,000 | |
| Net decrease in cash and cash equivalents | −3 | −4 | 6 | −17 | −9 | |
| Cash paid for taxes | 42,000 | 24,000 | 18,000 | 3,000 | 19,000 | |
| Transfer from Inventories to Equipment under lease, net | 5 | 9 | 4 | 2 | 4 |